Compare Ally Financial Inc (ALLY) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Amylx Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $43.92 (market cap $13.37B), while Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B). The key difference: Ally Financial Inc is far larger — about 5.1× Amylx Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | AMLX | |
|---|---|---|
Market Cap | $13.37B | $2.64B |
Sector | Financials | Health |
52-Week High | $47.25 | $24.19 |
52-Week Low | $35.96 | $7.82 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $44.14, up 0.8% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed earnings, beating estimates in Q1 2026 but missing in Q2, while maintaining a P/E of 10.34 and P/B of 0.99, indicating potential undervaluation. Recent news includes insider sales and corporate recognitions, alongside a declared $0.30 dividend payable in August 2026.
The outlook for ALLY is cautiously optimistic, with a consensus price target of $54.40 offering ~23% upside, though risks from higher provisions and macroeconomic pressures persist. Investment appeal lies in its low valuation and dividend, but investors must weigh credit risks and interest rate sensitivity against growth in auto finance and digital banking strengths.
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
